Namita Goyal
Expertise in
19
conditions

Dr. Namita Goyal

Neurology
UC Irvine Medical Center
200 S Manchester Ave Ste 110, 
Orange, CA 
Expertise in
19
conditions
UC Irvine Medical Center
200 S Manchester Ave Ste 110, 
Orange, CA 

Overview

Dr. Namita Goyal is a UCI Health neurologist with board certifications in neurology, electrodiagnostic medicine and neuromuscular medicine.

Dr. Goyal is highly rated in 19 conditions, according to our data. Her top areas of expertise are Inclusion Body Myositis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Myositis, and Primary Lateral Sclerosis.

Her clinical research consists of co-authoring 70 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency

University of Chicago, Neurology Residency

Specialties

Neurology

Licenses

Psychiatry & Neurology in MA

Board Certifications

CA State Medical License 2012 - 2024
MA State Medical License 2006 - 2023

Hospital Affiliations

UCI Medical Center

Languages Spoken

English

Gender

Female

Awards

Top Doctor Award, Orange County Medical Association
AB Baker Teacher Award, American Academy of Neurology

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UC Irvine Medical Center
200 S Manchester Ave Ste 110, Orange, CA 92868
Other Locations
UCI Health
101 The City Dr S, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: MN-166
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of Fosigotifator in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of Fosigotifator in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension
Enrollment Status: Terminated
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drug: ABBV-CLS-7262
Study Phase: Phase 1
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
Enrollment Status: Completed
Publish Date: December 12, 2024
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: No_longer_available
Publish Date: April 23, 2024
Intervention Type: Biological
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2024
A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
Enrollment Status: Completed
Publish Date: February 29, 2024
Intervention Type: Other, Biological
Study Phase: Phase 3
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Enrollment Status: Terminated
Publish Date: August 24, 2023
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 3
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Drug
Study Phase: Phase 3
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Drug
Study Drug: Memantine
Study Phase: Phase 2
Fluid Biomarkers With Deep Phenotyping in Patients With ALS
Fluid Biomarkers With Deep Phenotyping in Patients With ALS
Enrollment Status: Completed
Publish Date: December 16, 2021
A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis
A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: August 28, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
Enrollment Status: Completed
Publish Date: May 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

70 Total Publications

Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS.
Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS.
Journal: Biomedicines
Published: September 18, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Tahseen Mozaffar
Neurology
Expertise in
31
conditions
Dr. Tahseen Mozaffar
Neurology

UC Irvine Medical Center

200 S Manchester Ave Ste 110, 
Orange, CA 
 (9.4 miles away)
714-456-2332
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Tahseen Mozaffar is a Professor of Neurology, Orthopaedic Surgery and Pathology and Laboratory Medicine at University of California, Irvine. He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center and the Director of the Division of Neuromuscular Diseases. Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at University of California, Irvine. He is the Principal Investigator for UCI-NEXT, the NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by the NINDS/NIH.. Dr. Mozaffar is highly rated in 31 conditions, according to our data. His top areas of expertise are Pompe Disease, Inclusion Body Myositis, Myositis, Myasthenia Gravis, and Thymectomy.

Expertise in
24
conditions
Dr. Daniela Bota
Neurology
Expertise in
24
conditions
Dr. Daniela Bota
Neurology

UCI Health

101 The City Dr S, 
Orange, CA 
 (9.7 miles away)
714-456-8000
Languages Spoken:
English
See accepted insurances

Daniela Bota is a Neurologist in Orange, California. Dr. Bota is highly rated in 24 conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
33
conditions
Dr. Daniel W. Shrey
Neurology | Pediatric Neurology
Expertise in
33
conditions
Dr. Daniel W. Shrey
Neurology | Pediatric Neurology
1201 West La Veta Avenue, 
Orange, CA 
 (8.8 miles away)
888-770-2462
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Shrey is a Neurologist and a Pediatric Neurologist in Orange, California. Dr. Shrey is highly rated in 33 conditions, according to our data. His top areas of expertise are West Syndrome, Spasmus Nutans, Lennox-Gastaut Syndrome (LGS), and Epilepsy. Dr. Shrey is currently accepting new patients.

Frequently Asked Questions about Dr. Namita Goyal

How do I make an appointment with Dr. Namita Goyal?

You can book an appointment with Dr. Namita Goyal by calling their office at 714-456-2332. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Namita Goyal a top-rated expert for Inclusion Body Myositis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Namita Goyal is classified as an Elite expert for Inclusion Body Myositis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Namita Goyal specialize in?

While Dr. Namita Goyal is a Neurology, they have specific expertise in Inclusion Body Myositis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Myositis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Namita Goyal participate in research or clinical trials?

Yes. Dr. Namita Goyal has published 70 articles and abstracts on conditions like Inclusion Body Myositis. You can view a list of Dr. Namita Goyal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Namita Goyal accept my insurance?

Dr. Namita Goyal accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 714-456-2332 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goyal's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 57 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile